Antithymocyte immunoglobulin

Also known as: Anti-thymocyte globulin ATG

Active ingredient description

Antithymocyte immunoglobulin is a selective immunosuppressive agent mostly acting on T lymphocytes. Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Antithymocyte immunoglobulin (rabbit)
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA04

Medicines

Antithymocyte immunoglobulin is the active ingredient of these drugs:

Drug
Countries

Canada Estonia Hong Kong Ireland New Zealand

Austria Cyprus Estonia France Ireland

Brazil Ecuador France Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK

Unique ingredient identifier (UNII)

475247QF1Z - EQUINE THYMOCYTE IMMUNE GLOBULIN

CAS registry number

308067-60-9 - Antithymocyte immunoglobulin (rabbit)

SNOMED-CT

768651008 - Antithymocyte immunoglobulin (substance)